Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Trial Profile

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Phenelzine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms Epi-PRIMED
  • Sponsors EpiAxis Therapeutics
  • Most Recent Events

    • 12 Nov 2019 Status changed from recruiting to completed.
    • 01 Dec 2018 According to an EpiAxis Therapeutics media release, the company has expanded this study by including two additional recruitment centres. The two new centers are the Southern Medical Day Care Centre in Wollongong and at the Liverpool Cancer Therapy Centre. The principle investigators at these centre are Professor Phil Clingan and Dr Eugene Moylan, respectively.
    • 14 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top